The gastric neuroendocrine tumor market was valued at USD 1.85 Billion in 2024, driven by a supportive regulatory framework and growth in clinical trials across the 8 major markets. The market is expected to grow at a CAGR of 3.34% during the forecast period of 2025-2034, with the values likely to reach USD 2.57 Billion by 2034.
Base Year
Historical Year
Forecast Year
The presence of a supportive regulatory framework and significant research and development investments are stimulating market expansion.
The rise in the number of clinical trials exploring novel agents and combination therapies is anticipated to bolster market growth in the forecast period.
One of the major market trends is the growing adoption of targeted therapies and systemic treatments for gastric neuroendocrine tumors.
Value in USD Billion
2025-2034
Gastric Neuroendocrine Tumor Market Outlook
*this image is indicative*
Gastric neuroendocrine tumors refer to gastric neoplasm that originates from enterochromaffin type cells (neuroendocrine cells in the gastric mucosa). They belong to a broader category of gastroenteropancreatic neuroendocrine tumors. Somatostatin analogs for controlling the tumor are one of the therapeutic options for this disease.
Gastric neuroendocrine tumors are rare but have witnessed increasing incidence over the years. The rising diagnosis rates of these tumors as a result of advancements in diagnostic technologies and better awareness among healthcare providers are contributing to the market growth. The increasing development and adoption of targeted therapies such as octreotide and lanreotide are further supporting the market expansion. Moreover, the rise in the number of clinical trials exploring novel therapies is anticipated to bolster market growth in the coming years.
Favorable Regulatory Environment to Impact Market Growth
The presence of a supportive regulatory framework is one of the primary factors, stimulating the growth of the market and attracting substantial investments to advance treatment for gastric neuroendocrine tumors. For instance, in February 2024, two clinical-stage radiopharmaceutical companies RadioMedix, Inc., and Orano Med announced that their Targeted Alpha Therapy called AlphaMedixTM (212Pb-DOTAMTATE) had received Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA) for the treatment of gastroenteropancreatic neuroendocrine tumors. Such designations are projected to accelerate the development and review of novel agents, which is likely to boost market growth.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Market Breakup by Treatment Type
Market Breakup by Treatment Type
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on Treatment Type Covers a Significant Market Share
Based on the treatment type, the market is segmented into chemotherapy, immunotherapy, surgery, radiation therapy, and others. Chemotherapy is used in gastric neuroendocrine tumor cases where the tumor has spread to other parts of the body or in high-grade aggressive tumors. The commonly used chemotherapy drugs for gastric neuroendocrine tumors include streptozocin, doxorubicin, and cisplatin, among others. Immunotherapy such as immune checkpoint inhibitors is an emerging treatment option due to its potential to offer long-term control of the disease with fewer side effects.
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States holds a significant market share owing to the rising awareness among healthcare providers and the general public about the disease and substantial investment in research and development to find effective gastric neuroendocrine tumor treatments. The market also benefits from the availability of advanced diagnostic technologies, such as PET/CT scans, endoscopic procedures, and biomarkers, which facilitate early detection and accurate diagnosis of gastric neuroendocrine tumors and ensure timely intervention. Additionally, the rising demand for personalized medicine and targeted therapies is expected to fuel the market growth in the country.
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Novartis, based in Basel, Switzerland, is a multinational pharmaceutical corporation that plays a crucial role in market growth. In January 2024, the company presented the findings of the Phase III NETTER-2 trial at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, revealing that the combination of Lutathera® and long-acting release (LAR) octreotide significantly reduced the risk of disease progression or death by 72% as the first-line treatment in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Pfizer has a robust portfolio of medications across multiple therapeutic areas, including oncology. The company is actively involved in the development of novel therapies for rare and difficult-to-treat cancers such as gastric neuroendocrine tumors. Pfizer is leveraging its extensive research capabilities to explore targeted therapies and immuno-oncology agents in order to maintain its leading position in the market.
Boehringer Ingelheim, headquartered in Ingelheim am Rhein, Germany, is a key player in the market. The company is known for its strong pipeline of novel agents for various cancers, including gastric neuroendocrine tumors. It is involved in the clinical development of a new targeted immunotherapy, BI 764532, which is an investigational DLL3 that targets IgG-like T-cell engager, for the treatment of relapsed gastrointestinal tract, urogenital tract, and skin neuroendocrine carcinomas (epNEC).
American pharmaceutical company Eli Lilly and Company has a prominent presence in the market and is known for its strong focus on oncology, immunology, diabetes, and neuroscience. The company is actively engaged in the development of targeted treatments and immuno-oncology agents that might have the potential to treat gastric neuroendocrine tumors.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include F. Hoffmann-La Roche Ltd.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share